Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Income
$155.3M
Filings
3,658
Unique Clients
130
Active Period
2011–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · third_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Affordable Prescriptions for Patients Act
2026 · third_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Preserve Access to Affordable Generics and Biosimilars Act
2026 · third_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.1096
Increasing Transparency in Generic Drug Applications Act
2026 · third_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: S.1302
Prescription Pricing for the People Act of 2025
2026 · third_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act
Client expense: — · Firm income: $60,000
Matched citations: S.527
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: HR 3269
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: HR 3269
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: S. 2276
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: S. 2276
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Client: Fresenius Kabi
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: S. 2658
Medication Affordability and Patent Integrity Act
2026 · third_quarter · Client: Fresenius Kabi
Eliminating Thickets to Improve Competition (S. 2276 and HR 3269); Medication Affordability and Patent Integrity Act (S. 2658)
Client expense: — · Firm income: $30,000
Matched citations: S. 2658
Combating Organized Retail Crime Act of 2025
2026 · third_quarter · Client: WALGREEN COMPANY
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2853
Combating Organized Retail Crime Act
2026 · third_quarter · Client: WALGREEN COMPANY
Issues related to preventing organized retail crime, including the Combatting Organized Retail Crime Act: (H.R. 2853/S.1404)
Client expense: — · Firm income: $50,000
Matched citations: S.1404
Farm, Food, and National Security Act of 2024
2026 · third_quarter · Client: COALTION FOR ADULT BEVERAGE ALTERNATIVES
General hemp issues; H.R. 8467 - Family, Food, and National Security Act of 2024
Client expense: — · Firm income: $50,000
Matched citations: H.R. 8467
21st Century ROAD to Housing Act
2026 · third_quarter · Client: STANDARD INDUSTRIES LTD.
Issues relating to H.R. 6644; S. 2296; and S. 2651
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6644
National Defense Authorization Act for Fiscal Year 2026
2026 · third_quarter · Client: STANDARD INDUSTRIES LTD.
Issues relating to H.R. 6644; S. 2296; and S. 2651
Client expense: — · Firm income: $60,000
Matched citations: S. 2296
ROAD to Housing Act of 2025
2026 · third_quarter · Client: STANDARD INDUSTRIES LTD.
Issues relating to H.R. 6644; S. 2296; and S. 2651
Client expense: — · Firm income: $60,000
Matched citations: S. 2651
High-Capacity Grid Act
2026 · third_quarter · Client: NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION
Electrification policy; energy efficiency; grid and cyber security; transmissions; permitting reform; HR. 6633 High Capacity Grid Act alongside REWIRE Act
Client expense: — · Firm income: $50,000
Matched citations: HR. 6633
Vision Lab Choice Act of 2025
2026 · third_quarter · Client: AMERICAN OPTOMETRIC ASSOCIATION
Dental and Optometric Care Access Act; Vision Lab Choice Act S 1716
Client expense: — · Firm income: $50,000
Matched citations: S 1716
General healthcare policy issues, including Medicare Advantage, Medicare Part D and other payer policy matters, and health care clinical services; S.1105: No Unreasonable Payments, Coding, or Diagnoses for the Elderly Act; PL 119-21: One Big Beautiful Bill Act
Client expense: — · Firm income: $60,000
Matched citations: S.1105
Protect Our Letter Carriers Act of 2024
2026 · third_quarter · Client: NATIONAL ASSOCIATION OF LETTER CARRIERS
General Postal issues; H.R. 7629 - Protect Our Letter Carriers Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7629
The White Oak Resilience Act
2026 · third_quarter · Client: SAZERAC COMPANY, INC.
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2405
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Client expense: — · Firm income: $60,000
Matched citations: H.R. 471
White Oak Resiliency Act of 2025
2026 · third_quarter · Client: SAZERAC COMPANY, INC.
H.R. 2405 (White Oak Resilience Act) and S. 476 (White Oak Resilience Act) relating to the availability of white oak; forestry-related provisions in agriculture-related legislation; H.R. 471 (Fix Our Forests Act); issues related to intoxicating hemp
Client expense: — · Firm income: $60,000
Matched citations: S. 476
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
2026 · second_quarter · Client: VIATRIS (MYLAN, INC)
Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1843
Source: Senate LDA